Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection
GS Crowther, SD Baines, SL Todhunter… - Journal of …, 2013 - academic.oup.com
Objectives First-line treatment options for Clostridium difficile infection (CDI) are limited.
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
[PDF][PDF] Evaluation of NVB302 versus vancomycin activity in an in vitro human
GS Crowther, SD Baines, SL Todhunter… - J Antimicrob …, 2013 - researchgate.net
Objectives: First-line treatment options for Clostridium difficile infection (CDI) are limited.
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection
GS Crowther, SD Baines… - Journal of …, 2013 - researchprofiles.herts.ac.uk
OBJECTIVES: First-line treatment options for Clostridium difficile infection (CDI) are limited.
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection
GS Crowther, SD Baines, SL Todhunter… - Journal of …, 2013 - uhra.herts.ac.uk
OBJECTIVES: First-line treatment options for Clostridium difficile infection (CDI) are limited.
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
GS Crowther, SD Baines, SL Todhunter… - The Journal of …, 2012 - europepmc.org
Objectives First-line treatment options for Clostridium difficile infection (CDI) are limited.
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
[PDF][PDF] Evaluation of NVB302 versus vancomycin activity in an in vitro human
GS Crowther, SD Baines, SL Todhunter… - J Antimicrob …, 2013 - scholar.archive.org
Objectives: First-line treatment options for Clostridium difficile infection (CDI) are limited.
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection
GS Crowther, SD Baines… - The Journal of …, 2013 - pubmed.ncbi.nlm.nih.gov
Objectives First-line treatment options for Clostridium difficile infection (CDI) are limited.
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
GS Crowther, SD Baines… - Journal of …, 2013 - search.ebscohost.com
Objectives First-line treatment options for Clostridium difficile infection (CDI) are limited.
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …
NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared …